This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Verve Therapeutics (VERV) Soars 13.8%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Verve Therapeutics (VERV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
PTC Therapeutics (PTCT) Surges 5.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why
by Zacks Equity Research
SCYNEXIS' (SCYX) shares soar 134% year to date, owing to partnership with big wig GSK plc for the development of its antifungal tablet, Brexafemme.
Amylyx Pharmaceuticals, Inc. (AMLX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Amylyx Pharmaceuticals, Inc. (AMLX) delivered earnings and revenue surprises of 3,000% and 16.51%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Avalo Therapeutics, Inc. (AVTX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Avalo Therapeutics, Inc. (AVTX) delivered earnings and revenue surprises of 34.44% and 35.70%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Scynexis (SCYX) delivered earnings and revenue surprises of 10.71% and 24.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Scynexis (SCYX) Inks Antifungal Drug Deal With GSK
by Zacks Equity Research
Scynexis (SCYX) enters an exclusive license agreement with GSK to commercialize Brexafemme (ibrexafungerp), an antifungal tablet. GSK will also continue to develop ibrexafungerp for treating invasive candidiasis.
Scynexis (SCYX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Scynexis (SCYX) delivered earnings and revenue surprises of -21.57% and 17.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of -3.33% and 30.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Pacira (PCRX) Lags Q3 Earnings Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of -12.33% and 0.10%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Scynexis (SCYX) Q3 Earnings Expected to Decline
by Zacks Equity Research
Scynexis (SCYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Taro Pharmaceutical (TARO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Taro (TARO) delivered earnings and revenue surprises of -108.33% and 18.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Scynexis (SCYX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Scynexis (SCYX) delivered earnings and revenue surprises of 7.02% and 12.12%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Scynexis (SCYX) delivered earnings and revenue surprises of 31.08% and 1.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Scynexis (SCYX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Scynexis (SCYX) delivered earnings and revenue surprises of -47.89% and 53.90%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Scynexis (SCYX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Scynexis (SCYX) delivered earnings and revenue surprises of 92.41% and 3.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will SCYNEXIS Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in SCYNEXIS.
Scynexis (SCYX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Scynexis (SCYX) delivered earnings and revenue surprises of 4.55% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Scynexis (SCYX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Scynexis (SCYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for SCYNEXIS (SCYX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to SCYNEXIS (SCYX) stock based on the movements in the options market lately.
Scynexis (SCYX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Scynexis (SCYX) delivered earnings and revenue surprises of 11.11% and -5.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Scynexis (SCYX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Scynexis (SCYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Scynexis (SCYX) delivered earnings and revenue surprises of -20.00% and -24.71%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Scynexis (SCYX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Scynexis (SCYX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Scynexis (SCYX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Scynexis (SCYX) delivered earnings and revenue surprises of 30.00% and 6.67%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?